(Q28251212)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

review article

1 reference

title

Bisphosphonates: from bench to bedside (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author

Robert Graham G Russell

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

author name string

R Graham G Russell

series ordinal

1

0 references

language of work or name

English

0 references

publication date

1 April 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

Annals of the New York Academy of Sciences

26 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

volume

1068

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

page(s)

367-401

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

The small GTP-binding protein rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors

26 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

The small GTP-binding protein rac regulates growth factor-induced membrane ruffling

21 April 2017

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

Rho GTPases and the actin cytoskeleton

21 April 2017

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

Association of the human NPPS gene with ossification of the posterior longitudinal ligament of the spine (OPLL)

21 April 2017

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

Role of the mouse ank gene in control of tissue calcification and arthritis

21 April 2017

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

Autosomal dominant familial calcium pyrophosphate dihydrate deposition disease is caused by mutation in the transmembrane protein ANKH

21 April 2017

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

Mutations in ANKH cause chondrocalcinosis

21 April 2017

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

Autosomal dominant craniometaphyseal dysplasia is caused by mutations in the transmembrane protein ANK

21 April 2017

1 reference

https://api.crossref.org/works/10.1196/ANNALS.1346.041

Diphosphonates and Page's disease of bone.

21 April 2017

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates: from the laboratory to the clinic and back again

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates: preclinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

From molds and macrophages to mevalonate: a decade of progress in understanding the molecular mode of action of bisphosphonates.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates for treatment and prevention of bone metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

EXCRETION OF INORGANIC PYROPHOSPHATE IN HYPOPHOSPHATASIA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Structure-activity relationships of various bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Dichloromethylenebisphosphonate (Cl2MBP) inhibits bone resorption through injury to osteoclasts that resorb Cl2MBP-coated bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Kinetic studies of bone and mineral metabolism during treatment with (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate (APD) in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

The management of Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Paramyxoviruses and Paget's disease: the affirmative view

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Effect of dichloromethylene diphosphonate in Paget's disease of bone and in hypercalcaemia due to primary hyperparathyroidism or malignant disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Pamidronate. A review of its use in the management of osteolytic bone metastases, tumour-induced hypercalcaemia and Paget's disease of bone

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates and cancer-induced bone disease: beyond their antiresorptive activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

The role of bisphosphonates in the treatment of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Zoledronic acid to prevent skeletal complications in cancer: corroborating the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Efficacy of ibandronate in metastatic bone disease: review of clinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Osteonecrosis of the jaw and bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Effect of osteoporosis treatments on risk of non-vertebral fractures: review and meta-analysis of intention-to-treat studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Cyclic administration of pamidronate in children with severe osteogenesis imperfecta

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Intravenous zoledronic acid in postmenopausal women with low bone mineral density

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Esophagitis associated with the use of alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Regulation of osteoclast function

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Interaction between effects of parathyroid hormone and bisphosphonate on regulation of osteoclast activity by the osteoblast-like cell line UMR-106.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Comparison of cytotoxic effects of bisphosphonates in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Human osteoclast formation and activity in vitro: effects of alendronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates induce apoptosis in human myeloma cell lines: a novel anti-tumour activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

A possible mechanism of the specific action of bisphosphonates on osteoclasts: tiludronate preferentially affects polarized osteoclasts having ruffled borders

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Tiludronate inhibits protein tyrosine phosphatase activity in osteoclasts.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Clodronate and liposome-encapsulated clodronate are metabolized to a toxic ATP analog, adenosine 5'-(beta, gamma-dichloromethylene) triphosphate, by mammalian cells in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

The molecular mechanism of action of the antiresorptive and antiinflammatory drug clodronate: evidence for the formation in vivo of a metabolite that inhibits bone resorption and causes osteoclast and macrophage apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Further insight into mechanism of action of clodronate: inhibition of mitochondrial ADP/ATP translocase by a nonhydrolyzable, adenine-containing metabolite.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Heterocycle-containing bisphosphonates cause apoptosis and inhibit bone resorption by preventing protein prenylation: evidence from structure-activity relationships in J774 macrophages.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

The ability of statins to inhibit bone resorption is directly related to their inhibitory effect on HMG-CoA reductase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Genetic studies of disorders of calcium crystal deposition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Hypophosphatasia: molecular diagnosis of Rathbun's original case.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Alkaline phosphatase knock-out mice recapitulate the metabolic and skeletal defects of infantile hypophosphatasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Association of sporadic chondrocalcinosis with a -4-basepair G-to-A transition in the 5'-untranslated region of ANKH that promotes enhanced expression of ANKH protein and excess generation of extracellular inorganic pyrophosphate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Heterozygous mutations in ANKH, the human ortholog of the mouse progressive ankylosis gene, result in craniometaphyseal dysplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

The effect of risedronate on bone mineralization as measured by micro-computed tomography with synchrotron radiation: correlation to histomorphometric indices of turnover

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Risedronate preserves bone architecture in postmenopausal women with osteoporosis as measured by three-dimensional microcomputed tomography

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonate-induced osteopetrosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Manipulation of the anabolic and catabolic responses with OP-1 and zoledronic acid in a rat critical defect model

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Zoledronic acid causes enhancement of bone growth into porous implants.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Effect of pamidronate on bone turnover and implant migration after total hip arthroplasty: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Zoledronic acid prevents osteopenia and increases bone strength in a rabbit model of distraction osteogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Zoledronic Acid Treatment Results in Retention of Femoral Head Structure After Traumatic Osteonecrosis in Young Wistar Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

The use of alendronate to prevent early collapse of the femoral head in patients with nontraumatic osteonecrosis. A randomized clinical study

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Zoledronic acid improves femoral head sphericity in a rat model of perthes disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Interleukin-6 and tumor necrosis factor alpha levels after bisphosphonates treatment in vitro and in patients with malignancy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Quantitative structure-activity relationships for gammadelta T cell activation by bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Statins prevent bisphosphonate-induced gamma,delta-T-cell proliferation and activation in vitro.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Structure and mechanism of the farnesyl diphosphate synthase from Trypanosoma cruzi: implications for drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Inhibition of geranylgeranyl diphosphate synthase by bisphosphonates and diphosphates: a potential route to new bone antiresorption and antiparasitic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Effects of bisphosphonates on the growth of Entamoeba histolytica and Plasmodium species in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonates inhibit the growth of Trypanosoma brucei, Trypanosoma cruzi, Leishmania donovani, Toxoplasma gondii, and Plasmodium falciparum: a potential route to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Bisphosphonate inhibitors of Toxoplasma gondi growth: in vitro, QSAR, and in vivo investigations

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

(31)P NMR of apicomplexans and the effects of risedronate on Cryptosporidium parvum growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Radical cure of experimental cutaneous leishmaniasis by the bisphosphonate pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Metabolism of halogenated bisphosphonates by the cellular slime mould dictyostelium discoideum

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

Inhibition of growth of Dictyostelium discoideum amoebae by bisphosphonate drugs is dependent on cellular uptake

21 January 2018

1 reference

https://api.crossref.org/works/10.1196%2FANNALS.1346.041

21 January 2018

Identifiers

DOI

10.1196/ANNALS.1346.041

2 references

Consolidated OpenCitations Corpus – April 2017

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16831938%20AND%20SRC:MED&resulttype=core&format=json

26 December 2019

1 reference

Consolidated OpenCitations Corpus – April 2017

2 references

Consolidated OpenCitations Corpus – April 2017